Issue: November 2013
November 01, 2013
1 min read
Save

TAO

Issue: November 2013
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients received otamixaban with interim analysis conducted for otamixaban dose selection or received unfractionated heparin plus eptifibatide at the time of PCI.

TAO